- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kiniksa Pharmaceuticals Ltd (KNSA)
Kiniksa Pharmaceuticals Ltd stock price live, this page displays NASDAQ KNSA stock exchange data. View the KNSA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kiniksa Pharmaceuticals Ltd real time stock price chart below.
What Is the Kiniksa Pharmaceuticals Ltd Stock Price Today?
The Kiniksa Pharmaceuticals Ltd stock price today is 79.17.
What Is the Stock Symbol for Kiniksa Pharmaceuticals Ltd?
The stock ticker symbol for Kiniksa Pharmaceuticals Ltd is KNSA.
Is KNSA the Same as $KNSA?
$KNSA is a common way to refer to the Kiniksa Pharmaceuticals Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Kiniksa Pharmaceuticals Ltd Trade On?
Kiniksa Pharmaceuticals Ltd is listed and trades on the NASDAQ stock exchange.
Is Kiniksa Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Kiniksa Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Kiniksa Pharmaceuticals Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KNSA quote. (ISIN: GB00BRXB0C07)
What Is the Kiniksa Pharmaceuticals Ltd Stock Price Today?
The Kiniksa Pharmaceuticals Ltd stock price today is 79.17.
What Is the Stock Symbol for Kiniksa Pharmaceuticals Ltd?
The stock ticker symbol for Kiniksa Pharmaceuticals Ltd is KNSA.
Is KNSA the Same as $KNSA?
$KNSA is a common way to refer to the Kiniksa Pharmaceuticals Ltd ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Kiniksa Pharmaceuticals Ltd Trade On?
Kiniksa Pharmaceuticals Ltd is listed and trades on the NASDAQ stock exchange.
Is Kiniksa Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Kiniksa Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Kiniksa Pharmaceuticals Ltd share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KNSA quote. (ISIN: GB00BRXB0C07)
NASDAQ
Currency in USD
79.17
+0.70(+0.89%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
78.01
79.93
52 wk Range
32.89
82.94
KNSA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
78.0179.93
52 wk Range
32.8982.94
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KNSA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
98.00
Upside
+23.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 98.00
(+23.78% Upside)
Kiniksa Pharmaceuticals Ltd Earnings Call Summary for Q1/2026
- Kiniksa reported Q1 2026 EPS of $0.27, beating forecasts by 28.57%, with revenue of $214.3M exceeding expectations by 3.45%.
- Revenue surged 56% year-over-year driven by ARCALYST sales; net income jumped 166% to $22.6M with cash balance at $468.1M.
- Company raised full-year 2026 revenue guidance to $930M-$945M from previous $900M-$920M range, reflecting strong market expansion.
- Stock soared 21.51% post-earnings to $52.99, trading near 52-week high with 113% annual return despite slight pre-market decline.
- CEO cited milestone growth trajectory; challenges include rising R&D costs, ARCALYST awareness gap, and competitive pharmaceutical pressures.
Last Updated: 05/08/2026, 11:44 AM
Read Full TranscriptKiniksa Pharma investor slides for Q1/2026
Last Update: May 08, 2026
See full investor slides
Earnings
Latest Release
Jul 28, 2026
EPS / Forecast
0.30 / 0.31
Revenue / Forecast
243.6M / 226.56M
Compare KNSA to Peers and Sector
Metrics to compare | KNSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKNSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 76.6x | −2.3x | −0.3x | |
PEG Ratio | 0.05 | −0.05 | 0.00 | |
Price / Book | 9.4x | 2.7x | 2.6x | |
Price / LTM Sales | 7.3x | 5.5x | 3.1x | |
Upside (Analyst Target) | 25.5% | 260.5% | 47.6% | |
Fair Value Upside | Unlock | 12.8% | 5.6% | Unlock |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Kiniksa Pharma (KNSA) Stock Price Today?
The Kiniksa Pharma stock price today is 79.17 USD.
What Stock Exchange Does Kiniksa Pharma Trade On?
Kiniksa Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Kiniksa Pharma?
The stock symbol for Kiniksa Pharma is "KNSA."
What Is the Kiniksa Pharma Market Cap?
As of today, Kiniksa Pharma market cap is 6.19B USD.
What Is Kiniksa Pharma's Earnings Per Share (TTM)?
The Kiniksa Pharma EPS (TTM) is 0.99.
When Is the Next Kiniksa Pharma Earnings Date?
Kiniksa Pharma will release its next earnings report on Nov 03, 2026.
From a Technical Analysis Perspective, Is KNSA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Kiniksa Pharma Stock Split?
Kiniksa Pharma has split 0 times.
How Many Employees Does Kiniksa Pharma Have?
Kiniksa Pharma has 366 employees.
What is the current trading status of Kiniksa Pharma (KNSA)?
As of Aug 21, 2026, Kiniksa Pharma (KNSA) is trading at a price of 79.17 USD, with a previous close of 78.47 USD. The stock has fluctuated within a day range of 78.01 USD to 79.93 USD, while its 52-week range spans from 32.89 USD to 82.94 USD.
What Is Kiniksa Pharma (KNSA) Price Target According to Analysts?
The average 12-month price target for Kiniksa Pharma is 98.00 USD, with a high estimate of 108 USD and a low estimate of 87 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +23.78% Upside potential.
What Is the KNSA Premarket Price?
KNSA's last pre-market stock price is 77.69 USD. The pre-market share volume is 220.00, and the stock has decreased by -0.78, or -0.99%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.